Olema Pharmaceuticals Inc [NASDAQ: OLMA] stock went on a downward path that fall over -1.07% on Monday, amounting to a one-week price increase of more than 13.70%.
Over the last 12 months, OLMA stock dropped by -46.54%. The one-year Olema Pharmaceuticals Inc stock forecast points to a potential upside of 78.37. The average equity rating for OLMA stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $380.09 million, with 74.31 million shares outstanding and 54.65 million shares in the current float. Compared to the average trading volume of 963.16K shares, OLMA stock reached a trading volume of 1973285 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Olema Pharmaceuticals Inc [OLMA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for OLMA shares is $25.71 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on OLMA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Olema Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 02, 2024. While these analysts kept the previous recommendation, Citigroup raised their target price to Buy. The new note on the price target was released on January 30, 2024, representing the official price target for Olema Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $21, while Oppenheimer analysts kept a Outperform rating on OLMA stock.
The Average True Range (ATR) for Olema Pharmaceuticals Inc is set at 0.34 The Price to Book ratio for the last quarter was 1.01, with the Price to Cash per share for the same quarter was set at 6.35.
OLMA Stock Performance Analysis:
Olema Pharmaceuticals Inc [OLMA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.70. With this latest performance, OLMA shares gained by 65.97% in over the last four-week period, additionally sinking by -52.19% over the last 6 months – not to mention a drop of -46.54% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OLMA stock in for the last two-week period is set at 73.16, with the RSI for the last a single of trading hit 79.73, and the three-weeks RSI is set at 65.99 for Olema Pharmaceuticals Inc [OLMA]. The present Moving Average for the last 50 days of trading for this stock 4.31, while it was recorded at 5.33 for the last single week of trading, and 8.59 for the last 200 days.
Insight into Olema Pharmaceuticals Inc Fundamentals:
Olema Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.50 and a Current Ratio set at 10.50.
OLMA Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for OLMA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Olema Pharmaceuticals Inc go to -4.08%.
Olema Pharmaceuticals Inc [OLMA] Institutonal Ownership Details
The top three institutional holders of OLMA stocks are: BVF INC/IL with ownership of 9.14 million shares, which is approximately 16.2322%. PARADIGM BIOCAPITAL ADVISORS LP, holding 7.9 million shares of the stock with an approximate value of $$85.52 million in OLMA stocks shares; and PARADIGM BIOCAPITAL ADVISORS LP, currently with $$43.28 million in OLMA stock with ownership which is approximately 7.107%.
